دورية أكاديمية
Bergenin mitigates neuroinflammatory damage induced by high glucose: insights from Zebrafish, murine microbial cell line, and rat models.
| العنوان: | Bergenin mitigates neuroinflammatory damage induced by high glucose: insights from Zebrafish, murine microbial cell line, and rat models. |
|---|---|
| المؤلفون: | Yu W; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Luo R; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., He C; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Li Z; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Yang M; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Zhou J; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., He J; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Chen Q; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Song Z; School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China., Cheng S; Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.; Department of Science and Technology, Hunan University of Chinese Medicine, Changsha, Hunan, China. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2024 Aug 01; Vol. 15, pp. 1339178. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Background: The escalating global burden of diabetes and its associated cognitive impairment underscores the urgency for effective interventions. Bergenin shows promise in regulating glucose metabolism, mitigating inflammation, and improving cognitive function. Zebrafish models offer a unique platform for assessing drug efficacy and exploring pharmacological mechanisms, complemented by subsequent investigations in cell and rat models. Methods: The experimental subjects included zebrafish larvae (CZ98: Tg (mpeg1:EGFP) ihb20Tg/+ ), adult zebrafish (immersed in 2% glucose), BV2 cell line (50 mM glucose + 10 μm Aβ Results: 1) In zebrafish larvae, Bergenin interventions significantly reduced glucose levels and increased survival rates while decreasing teratogenicity rates. Microglial cell fluorescence in the brain notably decreased, and altered swimming behavior tended to normalize. 2) In adult zebrafish, Bergenin administration reduced BMI and blood glucose levels, altered swimming behavior to slower speeds and more regular trajectories, enhanced recognition ability, decreased brain glucose and lactate levels, weakened glycolytic enzyme activities, improved pathological changes in the telencephalon and gills, reduced expression of pro-inflammatory cytokines, decreased ins expression and increased expression of irs1 , irs2a , and irs2b , suggesting a reduction in insulin resistance. It also altered the expression of pparg and rela . 3) In BV2 cell line, Bergenin significantly reduced the protein expression of glycolytic enzymes (GLUT1, HK2, PKFKB3, and PKM2), lowered IL-1β, IL-6, and TNF-α mRNA expression, elevated PPAR-γ protein expression, and decreased P-NF-κB-p65 protein expression. 4) In the rat model, Bergenin improves learning and memory abilities in STZ-induced rats, mitigates neuronal damage in the hippocampal region, and reduces the expression of inflammatory factors IL-1β, IL-6, and TNF-α. Bergenin decreases brain glucose and lactate levels, as well as glycolytic enzyme activity. Furthermore, Bergenin increases PPARγ expression and decreases p-NF-κB p65/NF-κB p65 expression in the hippocampus. Conclusion: Bergenin intervenes through the PPAR-γ/NF-κB pathway, redirecting glucose metabolism, alleviating inflammation, and preventing high glucose-induced neuronal damage. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Yu, Luo, He, Li, Yang, Zhou, He, Chen, Song and Cheng.) |
| References: | Nat Neurosci. 2019 Nov;22(11):1806-1819. (PMID: 31636448) Am J Chin Med. 2023;51(7):1905-1925. (PMID: 37646142) J Diabetes Metab Disord. 2020 Oct 25;19(2):1233-1244. (PMID: 33553026) Neurosci Biobehav Rev. 2021 Aug;127:761-778. (PMID: 34087275) Front Immunol. 2021 Aug 09;12:716469. (PMID: 34434197) EMBO J. 2018 Nov 15;37(22):. (PMID: 30348863) Lipids Health Dis. 2023 Nov 24;22(1):203. (PMID: 38001454) Behav Brain Res. 2019 Jan 1;356:18-40. (PMID: 30118774) Chem Biol Drug Des. 2019 Jan;93(1):12-20. (PMID: 30187647) Front Pharmacol. 2022 Sep 29;13:994018. (PMID: 36249784) Front Pharmacol. 2018 Jan 12;8:981. (PMID: 29375382) Neural Regen Res. 2016 Sep;11(9):1492-1498. (PMID: 27857756) Mol Biol Rep. 2023 Nov;50(11):9129-9142. (PMID: 37749346) J Colloid Interface Sci. 2006 Oct 15;302(2):417-23. (PMID: 16876812) Cell Mol Neurobiol. 2023 Oct;43(7):3191-3210. (PMID: 37341833) Int J Mol Sci. 2020 Jul 09;21(14):. (PMID: 32659952) Lancet Neurol. 2020 Sep;19(9):758-766. (PMID: 32730766) Sci Rep. 2021 May 26;11(1):11048. (PMID: 34040051) Adv Sci (Weinh). 2024 Mar;11(10):e2305614. (PMID: 38151703) Free Radic Biol Med. 2019 Dec;145:118-135. (PMID: 31494242) Redox Biol. 2022 Apr;50:102236. (PMID: 35144052) Diabetologia. 2018 Apr;61(4):839-848. (PMID: 29368156) Ageing Res Rev. 2019 Nov;55:100944. (PMID: 31430566) Adv Clin Chem. 2022;108:37-71. (PMID: 35659061) Sci Rep. 2017 May 3;7(1):1461. (PMID: 28469250) Autophagy. 2020 Jan;16(1):52-69. (PMID: 30898012) Int J Mol Sci. 2020 Dec 02;21(23):. (PMID: 33276434) Front Cell Infect Microbiol. 2023 Nov 21;13:1323674. (PMID: 38076462) Acta Pharm Sin B. 2022 Nov;12(11):4011-4039. (PMID: 36386472) Sci Rep. 2024 May 27;14(1):12143. (PMID: 38802677) Apoptosis. 2022 Aug;27(7-8):509-520. (PMID: 35596834) Cureus. 2023 Jan 18;15(1):e33939. (PMID: 36819350) Yonsei Med J. 2018 Nov;59(9):1096-1106. (PMID: 30328325) Biomedicines. 2024 Mar 20;12(3):. (PMID: 38540306) Autophagy. 2023 Oct;19(10):2639-2656. (PMID: 37204119) J Vasc Res. 2022;59(4):251-260. (PMID: 35378543) Biomed Pharmacother. 2023 Dec;168:115736. (PMID: 37852100) Nat Rev Endocrinol. 2018 Mar;14(3):140-162. (PMID: 29348476) Int J Biol Sci. 2022 Jan 1;18(3):983-994. (PMID: 35173531) Front Endocrinol (Lausanne). 2023 Dec 13;14:1307432. (PMID: 38152139) Int J Mol Sci. 2020 Mar 05;21(5):. (PMID: 32150819) Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977) J Ethnopharmacol. 2024 Mar 1;321:117528. (PMID: 38043754) Wiley Interdiscip Rev Dev Biol. 2018 May;7(3):e312. (PMID: 29436122) Phytomedicine. 2020 May 16;76:153235. (PMID: 32563017) Adv Neurobiol. 2017;19:117-150. (PMID: 28933063) J Clin Invest. 2022 Mar 15;132(6):. (PMID: 35133975) Alzheimers Dement. 2021 Nov;17(11):1769-1778. (PMID: 34636485) Cell Death Dis. 2023 Mar 8;14(3):186. (PMID: 36882414) Acta Pharmacol Sin. 2022 Apr;43(4):963-976. (PMID: 34267342) Nat Rev Neurol. 2021 Mar;17(3):157-172. (PMID: 33318676) Front Pharmacol. 2024 Jan 12;14:1338804. (PMID: 38283834) Nurs Stand. 2022 Jan 5;37(1):61-66. (PMID: 34708622) J Alzheimers Dis. 2019;72(3):823-833. (PMID: 31658061) Appl Biochem Biotechnol. 2023 Sep;195(9):5299-5311. (PMID: 35622274) Semin Immunopathol. 2018 Feb;40(2):215-224. (PMID: 29209827) Pharm Res. 2022 Aug;39(8):1803-1815. (PMID: 35411507) Physiol Rev. 2019 Jan 1;99(1):949-1045. (PMID: 30565508) Nat Neurosci. 2024 May;27(5):1014-1018. (PMID: 38467902) Pharmacol Ther. 2023 May;245:108391. (PMID: 36963510) Invest Ophthalmol Vis Sci. 2023 Mar 1;64(3):35. (PMID: 37000125) Biomed Pharmacother. 2018 Jun;102:966-980. (PMID: 29710552) EMBO Rep. 2021 Jun 4;22(6):e52013. (PMID: 33998138) |
| فهرسة مساهمة: | Keywords: Zebrafish; bergenin; diabetes-associated cognitive impairment (DACI); glycolysis; neuroinflammation |
| تواريخ الأحداث: | Date Created: 20240816 Latest Revision: 20240817 |
| رمز التحديث: | 20240817 |
| مُعرف محوري في PubMed: | PMC11324488 |
| DOI: | 10.3389/fphar.2024.1339178 |
| PMID: | 39148536 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2024.1339178 |